<DOC>
	<DOCNO>NCT00904059</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics safety BMS-790052 BMS-650032 co-administered administer alone</brief_summary>
	<brief_title>Drug-Drug Interaction Study Healthy Subjects</brief_title>
	<detailed_description>Pharmacokinetics Safety Healthy Subjects</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Healthy male female subject age 18 49 year Females childbearing potential , pregnant breastfeeding Subject Body Mass Index ( BMI ) 18 32 kg/mÂ² Women child bear potential Male subject sex woman unwilling agree practice male barrier contraception study participation least 12 week follow dose Any significant acute chronic medical illness Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination Prior exposure BMS650032 BMS790052 Positive HIV HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>